Clinical Manifestations and Growth of Patients with Urea Cycle Disorders in Japan

Overview

Journal J Hum Genet

Specialty Genetics

Date 2016 Mar 4

PMID 26935171

Citations 2

Authors

Kimitoshi Nakamura

Jun Kido

Shirou Matsumoto

Hiroshi Mitsubuchi

Fumio Endo

Affiliations

Soon will be listed here.

Abstract

We have previously examined the clinical manifestations, treatments and prognosis of 177 patients with urea cycle disorders (UCDs) from January 1999 to March 2009 in Japan. In this study, we investigated the incidence of clinical manifestations in different peak blood ammonia level at onset in UCD patients, and examined the growth of OTCD (ornithine transcarbamylase deficiency) patients. The UCD patients who had a high peak blood ammonia level at onset showed significantly high incidence of convulsion and abnormal head computed tomography or magnetic resonance imaging. The patients also showed significantly high incidence of hemodialysis and liver transplantation. Choice of therapeutic agents for long-term treatment is not different between peak blood ammonia levels at the onset, except for the use of special amino-acid formulas. Growth retardation is not affected by high peak blood ammonia level at onset; however, 32% of male and 52% of female OTCD patients over 1 year old were plotted under the 10th percentile, and showed growth failure. The final height of the male and female OTCD patients were 166.2±5.5 and 150.3±7.2 cm, respectively. Although the prognosis of UCDs was improved significantly, it is considered that there are still many difficulties in the UCD patient's life.

Citing Articles

Physical, cognitive, and social status of patients with urea cycle disorders in Japan.

Kido J, Matsumoto S, Ito T, Hirose S, Fukui K, Kojima-Ishii K Mol Genet Metab Rep. 2021; 27:100724.

PMID: 33614409 PMC: 7876628. DOI: 10.1016/j.ymgmr.2021.100724.

Long-term effects of medical management on growth and weight in individuals with urea cycle disorders.

Posset R, Garbade S, Gleich F, Gropman A, de Lonlay P, Hoffmann G Sci Rep. 2020; 10(1):11948.

PMID: 32686765 PMC: 7371674. DOI: 10.1038/s41598-020-67496-3.

References

Uemoto S, Yabe S, Inomata Y, Nishizawa H, Asonuma K, Egawa H . Coexistence of a graft with the preserved native liver in auxiliary partial orthotopic liver transplantation from a living donor for ornithine transcarbamylase deficiency. Transplantation. 1997; 63(7):1026-8. DOI: 10.1097/00007890-199704150-00021. View

Feillet F, Leonard J . Alternative pathway therapy for urea cycle disorders. J Inherit Metab Dis. 1998; 21 Suppl 1:101-11. DOI: 10.1023/a:1005365825875. View

Maestri N, Brusilow S, Clissold D, Bassett S . Long-term treatment of girls with ornithine transcarbamylase deficiency. N Engl J Med. 1996; 335(12):855-9. DOI: 10.1056/NEJM199609193351204. View

Uchino T, Endo F, Matsuda I . Neurodevelopmental outcome of long-term therapy of urea cycle disorders in Japan. J Inherit Metab Dis. 1998; 21 Suppl 1:151-9. DOI: 10.1023/a:1005374027693. View

Brusilow S, Valle D, Batshaw M . New pathways of nitrogen excretion in inborn errors of urea synthesis. Lancet. 1979; 2(8140):452-4. DOI: 10.1016/s0140-6736(79)91503-4. View

Schaefer F, Straube E, Oh J, Mehls O, Mayatepek E . Dialysis in neonates with inborn errors of metabolism. Nephrol Dial Transplant. 1999; 14(4):910-8. DOI: 10.1093/ndt/14.4.910. View

Nakamura K, Kido J, Mitsubuchi H, Endo F . Diagnosis and treatment of urea cycle disorder in Japan. Pediatr Int. 2014; 56(4):506-9. DOI: 10.1111/ped.12439. View

Leonard J . The nutritional management of urea cycle disorders. J Pediatr. 2001; 138(1 Suppl):S40-4;discussion S44-5. DOI: 10.1067/mpd.2001.111835. View

Brusilow S . Phenylacetylglutamine may replace urea as a vehicle for waste nitrogen excretion. Pediatr Res. 1991; 29(2):147-50. DOI: 10.1203/00006450-199102000-00009. View

10.

Kido J, Nakamura K, Mitsubuchi H, Ohura T, Takayanagi M, Matsuo M . Long-term outcome and intervention of urea cycle disorders in Japan. J Inherit Metab Dis. 2011; 35(5):777-85. DOI: 10.1007/s10545-011-9427-0. View

11.

Smit G, Fernandes J, Leonard J, Matthews E, Moses S, Odievre M . The long-term outcome of patients with glycogen storage diseases. J Inherit Metab Dis. 1990; 13(4):411-8. DOI: 10.1007/BF01799498. View

12.

Nagasaka H, Yorifuji T, Murayama K, Kubota M, Kurokawa K, Murakami T . Effects of arginine treatment on nutrition, growth and urea cycle function in seven Japanese boys with late-onset ornithine transcarbamylase deficiency. Eur J Pediatr. 2006; 165(9):618-24. DOI: 10.1007/s00431-006-0143-y. View

13.

Matsuda I, Tanase S . The ornithine transcarbamylase (OTC) gene: mutations in 50 Japanese families with OTC deficiency. Am J Med Genet. 1997; 71(4):378-83. View

14.

Batshaw M, Macarthur R, Tuchman M . Alternative pathway therapy for urea cycle disorders: twenty years later. J Pediatr. 2001; 138(1 Suppl):S46-54; discussion S54-5. DOI: 10.1067/mpd.2001.111836. View

15.

Nassogne M, Heron B, Touati G, Rabier D, Saudubray J . Urea cycle defects: management and outcome. J Inherit Metab Dis. 2005; 28(3):407-14. DOI: 10.1007/s10545-005-0303-7. View

16.

Kido J, Nakamura K, Matsumoto S, Mitsubuchi H, Ohura T, Shigematsu Y . Current status of hepatic glycogen storage disease in Japan: clinical manifestations, treatments and long-term outcomes. J Hum Genet. 2013; 58(5):285-92. DOI: 10.1038/jhg.2013.17. View

17.

Matsuda I, Nagata N, Matsuura T, Oyanagi K, Tada K, Narisawa K . Retrospective survey of urea cycle disorders: Part 1. Clinical and laboratory observations of thirty-two Japanese male patients with ornithine transcarbamylase deficiency. Am J Med Genet. 1991; 38(1):85-9. DOI: 10.1002/ajmg.1320380119. View

18.

Haberle J, Boddaert N, Burlina A, Chakrapani A, Dixon M, Huemer M . Suggested guidelines for the diagnosis and management of urea cycle disorders. Orphanet J Rare Dis. 2012; 7:32. PMC: 3488504. DOI: 10.1186/1750-1172-7-32. View